JOURNAL ASMAC No 3 - juin 2018

PERSPECTIVES
Section d’hygiene du Secretariat de la Societe
des Nations = Weekly epidemiological
record/Health Section of the Secretariat of
the League of Nations. 2007; 82 (12):
93 – 104. Epub 2007/03/27.
3. Moberley S, Holden J, Tatham DP, Andrews
RM. Vaccines for preventing pneumococcal
infection in adults. Cochrane Database Syst
Rev. 2013; 1: CD000422. Epub 2013/02/27.
4. Huss A, Scott P, Stuck AE, Trotter C, Egger M.
Efficacy of pneumococcal vaccination in
adults: a meta-analysis. Cmaj. 2009; 180 (1):
48 – 58. Epub 2009/01/07.
5. Andrews NJ, Waight PA, George RC, Slack MP,
Miller E. Impact and effectiveness of 23-valent
pneumococcal polysaccharide vaccine
against invasive pneumococcal disease in
the elderly in England and Wales. Vaccine.
2012; 30 (48): 6802 – 8. Epub 2012/09/25.
6. Torling J, Hedlund J, Konradsen HB, Ortqvist
A. Revaccination with the 23-valent pneumococcal
polysaccharide vaccine in middleaged
and elderly persons previously treated
for pneumonia. Vaccine. 2003; 22 (1):
96 – 103.
7. O’Brien KL, Moulton LH, Reid R, Weatherholtz
R, Oski J, Brown L, et al. Efficacy and
safety of seven-valent conjugate pneumococcal
vaccine in American Indian children:
group randomised trial. Lancet. 2003; 362
(9381): 355 – 61.
8. Pilishvili T, Lexau C, Farley MM, Hadler J,
Harrison LH, Bennett NM, et al. Sustained
reductions in invasive pneumococcal disease
in the era of conjugate vaccine. J Infect Dis.
2010; 201 (1): 32 – 41.
9. Pollard AJ, Perrett KP, Beverley PC. Maintaining
protection against invasive bacteria
with protein-polysaccharide conjugate vaccines.
Nature reviews Immunology. 2009; 9
(3): 213 – 20. Epub 2009/02/14.
10. de Roux A, Schmole-Thoma B, Siber GR,
Hackell JG, Kuhnke A, Ahlers N, et al. Comparison
of pneumococcal conjugate polysaccharide
and free polysaccharide vaccines in
elderly adults: conjugate vaccine elicits improved
antibacterial immune responses and
immunological memory. Clin Infect Dis.
2008; 46 (7): 1015 – 23. Epub 2008/05/01.
11. Jackson LA, Gurtman A, van Cleeff M, Jansen
KU, Jayawardene D, Devlin C, et al. Immunogenicity
and safety of a 13-valent pneumococcal
conjugate vaccine compared to a
23-valent pneumococcal polysaccharide
vaccine in pneumococcal vaccine-naive
adults. Vaccine. 2013; 31 (35): 3577 – 84.
Epub 2013/05/22.
12. Greenberg RN, Gurtman A, Frenck RW,
Strout C, Jansen KU, Trammel J, et al. Sequential
administration of 13-valent pneumococcal
conjugate vaccine and 23-valent
pneumococcal polysaccharide vaccine in
pneumococcal vaccine-naive adults 60 – 64
years of age. Vaccine. 2014; 32 (20):
2364 – 74. Epub 2014/03/13.
13. Goldblatt D, Southern J, Andrews N, Ashton
L, Burbidge P, Woodgate S, et al. The immunogenicity
of 7-valent pneumococcal conjugate
vaccine versus 23-valent polysaccharide
vaccine in adults aged 50 – 80 years. Clin
Infect Dis. 2009; 49 (9): 1318 – 25. Epub
2009/10/10.
14. Black S, Shinefield H, Fireman B, Lewis E,
Ray P, Hansen JR, et al. Efficacy, safety and
immunogenicity of heptavalent pneumococcal
conjugate vaccine in children. Northern
California Kaiser Permanente Vaccine Study
Center Group. The Pediatric infectious disease
journal. 2000; 19 (3): 187 – 95.
15. Klugman KP, Madhi A, Huebner RE, Kohberger
R, Mbelle N, Pierce N, et al. Prevention
of pneumonia, invasive disease and antibiotic
– resistance by a 9-valent pneumococcal
conjugate vaccine in HIV-1 infected and
uninfected children. New Eng J Med. 2003;In
press.
16. Cutts FT, Zaman SM, Enwere G, Jaffar S,
Levine OS, Okoko JB, et al. Efficacy of ninevalent
pneumococcal conjugate vaccine
against pneumonia and invasive pneumococcal
disease in The Gambia: randomised,
double-blind, placebo-controlled trial. Lancet.
2005; 365 (9465): 1139 – 46.
17. Moore MR, Link-Gelles R, Schaffner W, Lynfield
R, Lexau C, Bennett NM, et al. Effect of
use of 13-valent pneumococcal conjugate
vaccine in children on invasive pneumococcal
disease in children and adults in the USA:
analysis of multisite, population-based surveillance.
Lancet Infect Dis. 2015; 15 (3):
301 – 9. Epub 2015/02/07.
18. Moore CE, Paul J, Foster D, Mahar SA, Griffiths
D, Knox K, et al. Reduction of invasive
pneumococcal disease 3 years after the introduction
of the 13-valent conjugate vaccine
in the Oxfordshire region of England. J Infect
Dis. 2014; 210 (7): 1001 – 11. Epub
2014/04/11.
19. Harboe ZB, Dalby T, Weinberger DM, Benfield
T, Molbak K, Slotved HC, et al. Impact
of 13-valent pneumococcal conjugate vaccination
in invasive pneumococcal disease
incidence and mortality. Clin Infect Dis.
2014; 59 (8): 1066 – 73. Epub 2014/07/19.
20. Pneumokokkenerkrankungen 2012. Bull
BAG. 2014 (4): 41 – 8. Epub 20.1.2014.
21. Meichtry J, Born R, Kuffer M, Zwahlen M,
Albrich WC, Brugger SD, et al. Serotype epidemiology
of invasive pneumococcal disease
in Swiss adults: a nationwide populationbased
study. Vaccine. 2014; 32 (40):
5185 – 91. Epub 2014/08/01.
22. Simonsen L, Taylor RJ, Young-Xu Y, Haber
M, May L, Klugman KP. Impact of pneumococcal
conjugate vaccination of infants on
pneumonia and influenza hospitalization
and mortality in all age groups in the United
States. mBio. 2011;2(1): e00309-10. Epub
2011/01/26.
23. Griffin MR, Zhu Y, Moore MR, Whitney CG,
Grijalva CG. U.S. hospitalizations for pneumonia
after a decade of pneumococcal vaccination.
N Engl J Med. 2013; 369 (2):
155 – 63. Epub 2013/07/12.
24. Ben-Shimol S, Givon-Lavi N, Leibovitz E,
Raiz S, Greenberg D, Dagan R. Near-elimination
of otitis media caused by 13-valent
pneumococcal conjugate vaccine (PCV)
serotypes in southern Israel shortly after
sequential introduction of 7-valent/13-valent
PCV. Clin Infect Dis. 2014; 59 (12):
1724 – 32. Epub 2014/08/28.
25. Veenhoven R, Bogaert D, Uiterwaal C, Brouwer
C, Kiezebrink H, Bruin J, et al. Effect of
conjugate pneumococcal vaccine followed
by polysaccharide pneumococcal vaccine on
recurrent acute otitis media: a randomised
study. Lancet. 2003; 361 (9376): 2189 – 95.
Epub 2003/07/05.
26. Kyaw MH, Lynfield R, Schaffner W, Craig AS,
Hadler J, Reingold A, et al. Effect of introduction
of the pneumococcal conjugate vaccine
on drug-resistant Streptococcus pneumoniae.
N Engl J Med. 2006; 354 (14): 1455 – 63.
27. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends
in acute otitis media-related health care
utilization by privately insured young children
in the United States, 1997 – 2004. Pediatrics.
2008; 121 (2): 253 – 60. Epub
2008/02/05.
28. Richter SS, Diekema DJ, Heilmann KP,
Dohrn CL, Riahi F, Doern GV. Changes in
pneumococcal serotypes and antimicrobial
resistance after introduction of the 13-valent
conjugate vaccine in the United States. Antimicrob
Agents Chemother. 2014; 58 (11):
6484 – 9. Epub 2014/08/20.
29. French N, Gordon SB, Mwalukomo T, White
SA, Mwafulirwa G, Longwe H, et al. A trial of
a 7-valent pneumococcal conjugate vaccine
in HIV-infected adults. N Engl J Med. 2010;
362 (9): 812 – 22.
30. Bonten MJ, Huijts SM, Bolkenbaas M, Webber
C, Patterson S, Gault S, et al. Polysaccharide
conjugate vaccine against pneumococcal
pneumonia in adults. N Engl J Med. 2015;
372 (12): 1114 – 25. Epub 2015/03/19.
31. Bundesamt für Gesundheit (BAG) und Eidgenössische
Kommission für Impffragen
(EKIF). Pneumokokkenimpfung: Empfehlungen
zur Verhinderung von invasiven
Pneumokokkenerkrankungen bei Risikogruppen.
Bull BAG. 2014; 8: 129 – 41. Epub
17. Februar 2014.
32. Bundesamt für Gesundheit (BAG) und Eidgenössische
Kommission für Impffragen
(EKIF). Schweizerischer Impfplan 2016.
Richtlinien und Empfehlungen. Bern: Bundesamt
für Gesundheit, 2016.
33. Albrich WC. Schutz vor dem “Captain of the
men of death”. Neues zur Pneumokokkenprävention:
warum, für wen, womit? Swiss
Med Forum. 2014; 14 (51 – 52): 973 – 5.
34. Bundesministerium für Gesundheit. Impfplan
Österreich. In: Gesundheit Bf, 2016.
35. Ständige Impfkommission (STIKO). Empfehlungen
der Ständigen Impfkommission
(STIKO) am Robert Koch-Institut/Stand:
August 2015. Epidemiologisches Bulletin.
2015; 34: 327 – 62.
N o 3 juin 2018
VSAO JOURNAL ASMAC
49